JPH07502497A - 安定化抗体 - Google Patents
安定化抗体Info
- Publication number
- JPH07502497A JPH07502497A JP5507258A JP50725893A JPH07502497A JP H07502497 A JPH07502497 A JP H07502497A JP 5507258 A JP5507258 A JP 5507258A JP 50725893 A JP50725893 A JP 50725893A JP H07502497 A JPH07502497 A JP H07502497A
- Authority
- JP
- Japan
- Prior art keywords
- immunoglobulin
- antibody
- copper
- composition according
- immunoglobulins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
Abstract
Description
Claims (21)
- 1.少なくとも1種の免疫グロブリンを、安定化量の銅イオンキレート剤と共に 含有する安定化免疫グロブリン組成物。
- 2.免疫グロブリンがクラスIgGの免疫グロブリンである請求の範囲第1項記 載の組成物。
- 3.免疫グロブリンが組換えCDR−グラフト化抗体である請求の範囲第1項ま たは第2項に記載の組成物。
- 4.抗体が、CD2、CD3、CD4、CD5、CD7、CD8、CD118、 b、CD18、CD19、CD25、CD33、CDw52またはCD54抗原 に対する抗体である請求の範囲第3項記載の組成物。
- 5.抗体がCDw52抗原に対する抗体である請求の範囲第3項記載の組成物。
- 6.抗体がCAMPATH−IHである請求の範囲第5項記載の組成物。
- 7.銅イオンキレート剤がエチレンジアミン四酢酸である請求の範囲第1項ない し第6項のいずれか1項に記載の組成物。
- 8.銅イオンキレート剤がクエン酸イオンである請求の範囲第1項ないし第6項 のいずれか1項に記載の組成物。
- 9.非経口投与に適した液体製剤の形態にある請求の範囲第1項ないし第8項の いずれか1項に記載の組成物。
- 10.非経口投与に適した液体製剤に戻すことに適合する凍結乾燥形態にある請 求の範囲第1項ないし第8項のいずれか1項に記載の組成物。
- 11.保存時の分解に対する免疫グロブリンの安定化への銅イオンキレート剤の 使用。
- 12.銅イオンキレート剤がエチレンジアミン四酢酸である請求の範囲第11項 記載の使用。
- 13.銅イオンキレート剤がクエン酸塩である請求の範囲第11項記載の使用。
- 14.抗体がCDw52抗原に対する組換えCDR−グラフト化抗体である請求 の範囲第11項ないし第13項のいずれか1項に記載の使用。
- 15.抗体がCAMPATH−IHである請求の範囲第14項記載の使用。
- 16.免疫グロブリンに、それらから銅イオンを除去することが可能な精製手順 を施すことを包含する免疫グロブリンの安定性の増強方法。
- 17.精製手順が、リン酸緩衝液を含有するシアン化カリウムに対する透析と、 それに続く、銅をシアン化銅として除去するためのゲル濾過である請求の範囲第 16項記載の方法。
- 18.実質的に銅イオンを含有しない精製免疫グロブリン。
- 19.原子吸光分光分析によって銅を検出することができない精製免疫グロブリ ン。
- 20.CDW52抗原に対する組換えCDR−グラフト化抗体である請求の範囲 第18項または第19項に記載の免疫グロブリン。
- 21.抗体がCAMPATH−IHである請求の範囲第20項記載の免疫グロブ リン。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9122820.5 | 1991-10-28 | ||
GB919122820A GB9122820D0 (en) | 1991-10-28 | 1991-10-28 | Stabilised antibodies |
PCT/GB1992/001970 WO1993008837A1 (en) | 1991-10-28 | 1992-10-27 | Stabilised antibodies |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH07502497A true JPH07502497A (ja) | 1995-03-16 |
JP2881499B2 JP2881499B2 (ja) | 1999-04-12 |
Family
ID=10703637
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP5507258A Expired - Lifetime JP2881499B2 (ja) | 1991-10-28 | 1992-10-27 | 安定化抗体 |
Country Status (17)
Country | Link |
---|---|
US (2) | US5654403A (ja) |
EP (1) | EP0612251B1 (ja) |
JP (1) | JP2881499B2 (ja) |
AT (1) | ATE161191T1 (ja) |
AU (1) | AU674290B2 (ja) |
CA (1) | CA2121257C (ja) |
DE (1) | DE69223641T2 (ja) |
DK (1) | DK0612251T3 (ja) |
ES (1) | ES2112338T3 (ja) |
GB (1) | GB9122820D0 (ja) |
GR (1) | GR3025931T3 (ja) |
HK (1) | HK1004325A1 (ja) |
IL (1) | IL103560A (ja) |
MY (1) | MY110207A (ja) |
SG (1) | SG47905A1 (ja) |
WO (1) | WO1993008837A1 (ja) |
ZA (1) | ZA928296B (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005033143A1 (ja) * | 2003-10-01 | 2005-04-14 | Kyowa Hakko Kogyo Co., Ltd. | 抗体の安定化方法及び安定化された溶液状抗体製剤 |
WO2005035573A1 (ja) * | 2003-10-09 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | タンパク質溶液の安定化方法 |
WO2005063291A1 (ja) * | 2003-12-25 | 2005-07-14 | Kirin Beer Kabushiki Kaisha | 抗体を含有する安定な水性医薬製剤 |
US7709615B2 (en) | 2003-07-15 | 2010-05-04 | Chugai Seiyaku Kabushiki Kaisha | Polynucleotides encoding anti-ganglioside antibodies |
US8920797B2 (en) | 2003-10-09 | 2014-12-30 | Chugai Seiyaku Kabushiki Kaisha | Highly concentrated stabilized IgM solution |
US10233247B2 (en) | 1999-04-09 | 2019-03-19 | Kyowa Hakko Kirin Co., Ltd | Method of modulating the activity of functional immune molecules |
US10233475B2 (en) | 2000-10-06 | 2019-03-19 | Kyowa Hakko Kirin Co., Ltd | Antibody composition-producing cell |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5976832A (en) * | 1995-03-06 | 1999-11-02 | Tonen Corporation | DNA encoding novel calcium-binding proteins |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
PT907735E (pt) * | 1996-05-24 | 2006-06-30 | Biogen Idec Inc | Moduladores da regeneracao de tecidos |
US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
US6991790B1 (en) | 1997-06-13 | 2006-01-31 | Genentech, Inc. | Antibody formulation |
DK1068238T3 (da) * | 1998-04-02 | 2013-01-14 | Xintela Ab | Integrinheterodimer og subunit deraf |
US20030055231A1 (en) * | 1998-10-28 | 2003-03-20 | Jian Ni | 12 human secreted proteins |
US6914128B1 (en) * | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
US7883704B2 (en) * | 1999-03-25 | 2011-02-08 | Abbott Gmbh & Co. Kg | Methods for inhibiting the activity of the P40 subunit of human IL-12 |
WO2000058480A1 (fr) * | 1999-03-29 | 2000-10-05 | Kansai Technology Licensing Organization Co., Ltd. | Nouvelle cytidine desaminase |
SE9902056D0 (sv) * | 1999-06-03 | 1999-06-03 | Active Biotech Ab | An integrin heterodimer and an alpha subunit thereof |
US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
US20020035107A1 (en) * | 2000-06-20 | 2002-03-21 | Stefan Henke | Highly concentrated stable meloxicam solutions |
US20020141970A1 (en) * | 2001-03-05 | 2002-10-03 | Pettit Dean K. | Stable aqueous solutions of granulocyte macrophage colony-stimulating factor |
NZ528483A (en) * | 2001-04-05 | 2008-03-28 | Astellas Pharma Inc | Anti-osteopontin antibody and use thereof |
EP3192528A1 (en) * | 2002-02-14 | 2017-07-19 | Chugai Seiyaku Kabushiki Kaisha | Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
JP5116971B2 (ja) | 2002-10-15 | 2013-01-09 | インターセル アーゲー | B群連鎖球菌の接着因子をコードする核酸、b群連鎖球菌の接着因子、およびその使用 |
MY150740A (en) * | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
EP1568369A1 (en) | 2004-02-23 | 2005-08-31 | Boehringer Ingelheim Vetmedica Gmbh | Use of meloxicam for the treatment of respiratory diseases in pigs |
PT1730191E (pt) | 2004-03-30 | 2011-10-04 | Glaxo Group Ltd | Imunoglobulina que se liga a hosm |
TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
US20090238820A1 (en) * | 2005-03-08 | 2009-09-24 | Allan Corey M | ANTI-MAdCAM ANTIBODY COMPOSITIONS |
CA2607663C (en) * | 2005-05-19 | 2014-08-12 | Amgen Inc. | Compositions and methods for increasing the stability of antibodies |
EP3673919A1 (en) | 2005-06-14 | 2020-07-01 | Amgen Inc. | Self-buffering protein formulations |
AR059066A1 (es) | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
US20110008282A1 (en) * | 2006-05-15 | 2011-01-13 | Xbiotech, Inc. | IL-1alpha immunization induces autoantibodies protective against atherosclerosis |
WO2007135546A2 (en) * | 2006-05-22 | 2007-11-29 | Xbiotech Inc. | TREATMENT OF CANCER WITH ANTI-IL-1α ANTIBODIES |
WO2008045373A2 (en) * | 2006-10-06 | 2008-04-17 | Amgen Inc. | Stable antibody formulations |
EP2094247B1 (en) * | 2006-10-20 | 2022-06-29 | Amgen Inc. | Stable polypeptide formulations |
SG177982A1 (en) | 2007-01-16 | 2012-02-28 | Abbott Lab | Methods for treating psoriasis |
US8168760B2 (en) | 2007-03-29 | 2012-05-01 | Abbott Laboratories | Crystalline anti-human IL-12 antibodies |
US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
EP2274333A4 (en) * | 2008-03-18 | 2011-06-15 | Abbott Lab | PROCESS FOR TREATING PSORIASIS |
WO2009148575A1 (en) * | 2008-05-30 | 2009-12-10 | Xbiotech, Inc. | Interleukin-1 alpha abs and methods of use |
AU2009291536B2 (en) * | 2008-09-12 | 2012-08-16 | Xbiotech Inc. | Targeting pathogenic monocytes |
NZ592644A (en) * | 2008-11-28 | 2013-09-27 | Abbott Lab | Stable antibody compositions and methods for stabilizing same |
AR074777A1 (es) | 2008-12-19 | 2011-02-09 | Glaxo Group Ltd | Proteinas de union a antigeno |
GB0904355D0 (en) * | 2009-03-13 | 2009-04-29 | Imp Innovations Ltd | Biological materials and uses thereof |
NZ595694A (en) * | 2009-05-04 | 2013-09-27 | Abbvie Biotechnology Ltd | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies |
RU2012114854A (ru) * | 2009-09-14 | 2013-10-27 | Эбботт Лэборетриз | Способы лечения псориаза |
US20110071276A1 (en) * | 2009-09-24 | 2011-03-24 | Xbiotech, Inc. | Method of modifying a monoclonal antibody |
CA2778401C (en) * | 2009-10-21 | 2019-08-13 | Hiroshima University | Integrin alpha 8-beta 1-specific monoclonal antibody |
JP5850860B2 (ja) | 2010-01-28 | 2016-02-03 | グラクソ グループ リミテッドGlaxo Group Limited | Cd127結合タンパク質 |
WO2011098424A2 (en) | 2010-02-09 | 2011-08-18 | Glaxo Group Limited | Treatment of a metabolic disorder |
CA3101298A1 (en) | 2010-03-01 | 2011-09-09 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
UA108227C2 (xx) | 2010-03-03 | 2015-04-10 | Антигензв'язуючий білок | |
UY33421A (es) | 2010-06-03 | 2011-12-30 | Glaxo Wellcome House | Proteinas de union al antígeno humanizados |
KR20130098279A (ko) | 2010-06-18 | 2013-09-04 | 엑스바이오테크, 인크. | 관절염 치료 |
ES2856723T3 (es) | 2010-08-23 | 2021-09-28 | Janssen Biotech Inc | Tratamiento para enfermedades neoplásicas |
EP2444101A1 (en) | 2010-10-21 | 2012-04-25 | Universitätsklinikum Freiburg | Selective targeting of the CD40L/Mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis |
TWI603739B (zh) | 2010-11-11 | 2017-11-01 | 艾伯維生物技術有限責任公司 | 具有增進高濃度之抗-TNFα抗體之液體調配物 |
US9724409B2 (en) | 2011-04-01 | 2017-08-08 | Xbiotech, Inc. | Treatment of inflammatory skin disease |
EP2702077A2 (en) | 2011-04-27 | 2014-03-05 | AbbVie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
WO2013043973A2 (en) | 2011-09-23 | 2013-03-28 | Xbiotech, Inc. | Cachexia treatment |
US9895437B2 (en) | 2012-04-18 | 2018-02-20 | Valneva Austria Gmbh | Aluminum compounds for use in therapeutics and vaccines |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
US8883979B2 (en) | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
AU2013309506A1 (en) | 2012-09-02 | 2015-03-12 | Abbvie Inc. | Methods to control protein heterogeneity |
US9545441B2 (en) | 2012-09-18 | 2017-01-17 | Xbiotech, Inc. | Treatment of diabetes |
AU2013381687A1 (en) | 2013-03-12 | 2015-09-24 | Abbvie Inc. | Human antibodies that bind human TNF-alpha and methods of preparing the same |
WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
EP2968550B1 (en) * | 2013-03-14 | 2018-11-14 | Ffe Therapeutics LLC | Compositions and methods for treating angiogenesis-related disorders |
US8921526B2 (en) | 2013-03-14 | 2014-12-30 | Abbvie, Inc. | Mutated anti-TNFα antibodies and methods of their use |
EP3052640A2 (en) | 2013-10-04 | 2016-08-10 | AbbVie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
WO2016059602A2 (en) | 2014-10-16 | 2016-04-21 | Glaxo Group Limited | Methods of treating cancer and related compositions |
PT3334747T (pt) | 2015-08-13 | 2023-12-12 | Amgen Inc | Formulação de gonadotrofina líquida estável |
WO2017049529A1 (en) | 2015-09-24 | 2017-03-30 | Innolife Co., Ltd. | A pharmaceutical composition comprising a copper chelating tetramine and the use thereof |
EP3582813A4 (en) | 2017-02-16 | 2020-12-30 | XBiotech, Inc | TREATMENT OF SUPPURATIVE HIDRADENITIS |
CN110408600A (zh) * | 2018-12-10 | 2019-11-05 | 浙江工商大学 | 一株分泌抗重金属铜离子单克隆抗体的杂交瘤细胞株及其应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2149304A (en) * | 1936-04-20 | 1939-03-07 | Sharp & Dohme Inc | Lyophilic biologically active substances |
JPS56145222A (en) * | 1980-04-28 | 1981-11-11 | Toshiyuki Hamaoka | Improved antibody and its preparation |
CA1308023C (en) * | 1988-07-29 | 1992-09-29 | William Austin James Mcauley | Immunoglobulin extraction utilizing properties of colloidal solutions |
US4933435A (en) * | 1989-04-05 | 1990-06-12 | Bioprobe International | Antibody purification process |
GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
GB9022543D0 (en) * | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
JPH0565233A (ja) * | 1991-03-08 | 1993-03-19 | Mitsui Toatsu Chem Inc | モノクローナル抗体含有凍結乾燥製剤 |
US5367060A (en) * | 1991-05-24 | 1994-11-22 | Genentech, Inc. | Structure, production and use of heregulin |
-
1991
- 1991-10-28 GB GB919122820A patent/GB9122820D0/en active Pending
-
1992
- 1992-10-27 ES ES92922609T patent/ES2112338T3/es not_active Expired - Lifetime
- 1992-10-27 WO PCT/GB1992/001970 patent/WO1993008837A1/en active IP Right Grant
- 1992-10-27 JP JP5507258A patent/JP2881499B2/ja not_active Expired - Lifetime
- 1992-10-27 IL IL103560A patent/IL103560A/en not_active IP Right Cessation
- 1992-10-27 EP EP92922609A patent/EP0612251B1/en not_active Expired - Lifetime
- 1992-10-27 CA CA002121257A patent/CA2121257C/en not_active Expired - Lifetime
- 1992-10-27 AU AU28729/92A patent/AU674290B2/en not_active Expired
- 1992-10-27 US US08/232,127 patent/US5654403A/en not_active Expired - Lifetime
- 1992-10-27 AT AT92922609T patent/ATE161191T1/de active
- 1992-10-27 ZA ZA928296A patent/ZA928296B/xx unknown
- 1992-10-27 DE DE69223641T patent/DE69223641T2/de not_active Expired - Lifetime
- 1992-10-27 SG SG1996005153A patent/SG47905A1/en unknown
- 1992-10-27 DK DK92922609.0T patent/DK0612251T3/da active
- 1992-10-27 MY MYPI92001936A patent/MY110207A/en unknown
-
1995
- 1995-06-05 US US08/465,319 patent/US5792838A/en not_active Expired - Lifetime
-
1998
- 1998-01-15 GR GR980400101T patent/GR3025931T3/el unknown
- 1998-04-22 HK HK98103367A patent/HK1004325A1/xx not_active IP Right Cessation
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10233247B2 (en) | 1999-04-09 | 2019-03-19 | Kyowa Hakko Kirin Co., Ltd | Method of modulating the activity of functional immune molecules |
US10233475B2 (en) | 2000-10-06 | 2019-03-19 | Kyowa Hakko Kirin Co., Ltd | Antibody composition-producing cell |
US7709615B2 (en) | 2003-07-15 | 2010-05-04 | Chugai Seiyaku Kabushiki Kaisha | Polynucleotides encoding anti-ganglioside antibodies |
US8257703B2 (en) | 2003-07-15 | 2012-09-04 | Chugai Seiyaku Kabushiki Kaisha | Anti-ganglioside antibodies and compositions |
US8496930B2 (en) | 2003-10-01 | 2013-07-30 | Kyowa Hakko Kirin Co., Ltd | Method of stabilizing antibody and stabilized solution-type antibody preparation |
US10172790B2 (en) | 2003-10-01 | 2019-01-08 | Kyowa Hakko Kirin Co., Ltd | Method of stabilizing antibody and stabilized solution-type antibody preparation |
US9011850B2 (en) | 2003-10-01 | 2015-04-21 | Kyowa Hakko Kirin Co., Ltd | Method of stabilizing antibody and stabilized solution-type antibody preparation |
WO2005033143A1 (ja) * | 2003-10-01 | 2005-04-14 | Kyowa Hakko Kogyo Co., Ltd. | 抗体の安定化方法及び安定化された溶液状抗体製剤 |
US7803914B2 (en) | 2003-10-09 | 2010-09-28 | Chugai Seiyaku Kabushiki Kaisha | Methods for stabilizing protein solutions |
US8920797B2 (en) | 2003-10-09 | 2014-12-30 | Chugai Seiyaku Kabushiki Kaisha | Highly concentrated stabilized IgM solution |
JPWO2005035573A1 (ja) * | 2003-10-09 | 2008-01-17 | 中外製薬株式会社 | タンパク質溶液の安定化方法 |
EP1686137A1 (en) * | 2003-10-09 | 2006-08-02 | Chugai Seiyaku Kabushiki Kaisha | Method of stabilizing protein solutions |
WO2005035573A1 (ja) * | 2003-10-09 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | タンパク質溶液の安定化方法 |
WO2005063291A1 (ja) * | 2003-12-25 | 2005-07-14 | Kirin Beer Kabushiki Kaisha | 抗体を含有する安定な水性医薬製剤 |
Also Published As
Publication number | Publication date |
---|---|
CA2121257C (en) | 1999-07-13 |
ZA928296B (en) | 1994-04-28 |
WO1993008837A1 (en) | 1993-05-13 |
MY110207A (en) | 1998-02-28 |
US5654403A (en) | 1997-08-05 |
ATE161191T1 (de) | 1998-01-15 |
CA2121257A1 (en) | 1993-05-13 |
IL103560A0 (en) | 1993-03-15 |
US5792838A (en) | 1998-08-11 |
GB9122820D0 (en) | 1991-12-11 |
ES2112338T3 (es) | 1998-04-01 |
IL103560A (en) | 1998-02-08 |
DE69223641D1 (de) | 1998-01-29 |
GR3025931T3 (en) | 1998-04-30 |
JP2881499B2 (ja) | 1999-04-12 |
EP0612251A1 (en) | 1994-08-31 |
EP0612251B1 (en) | 1997-12-17 |
DK0612251T3 (da) | 1998-04-27 |
SG47905A1 (en) | 1998-04-17 |
HK1004325A1 (en) | 1998-11-20 |
AU674290B2 (en) | 1996-12-19 |
AU2872992A (en) | 1993-06-07 |
DE69223641T2 (de) | 1998-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH07502497A (ja) | 安定化抗体 | |
JP7366747B2 (ja) | 血液凝固抗体 | |
JP5307030B2 (ja) | PEG化AβFAB | |
CA2254983A1 (en) | Concentrated antibody preparation | |
AU2017346401B2 (en) | Long acting multi-specific molecules and related methods | |
EP3807316B1 (en) | Compositions and methods for treating cancer | |
TWI716059B (zh) | 經改良的促凝血抗體 | |
US20220372127A1 (en) | Aqueous pharmaceutical composition of an anti-il17a antibody and use thereof | |
EP3714901A1 (en) | Lag-3 antibody pharmaceutical composition and use thereof | |
EP3795591A1 (en) | Cys80 conjugated immunoglobulins | |
EP3848049A1 (en) | Anti-tim3 antibody pharmaceutical composition and use thereof | |
EP4130036A1 (en) | Antibody drug conjugate | |
KR20220152172A (ko) | Cd47 및 pd-l1에 특이적으로 결합하는 이중특이적 항체 | |
WO2024102523A1 (en) | Glycosynthase variants for antibody-drug conjugate engineering | |
JP2024512351A (ja) | Gdf-15に対する抗体 | |
CN116474090A (zh) | 药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080205 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090205 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090205 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100205 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100205 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110205 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110205 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120205 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130205 Year of fee payment: 14 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130205 Year of fee payment: 14 |